Skip to main content
. 2022 May 9;7(9):e152731. doi: 10.1172/jci.insight.152731

Figure 6. Inhibiting MNKs enhances an immunosuppressive phenotype in tumor-associated macrophages (TAMs).

Figure 6

Established syngeneic mouse thyroid (TBP-3868) and pancreatic (KPC-344) tumors were treated with CGP57380 (25 mg/kg) or eFT508 (1 mg/kg) daily for 2 weeks. (A and B) The tumors were stained for F4/80 and Arginase-1 by IHC. Scale bar: 100 μm. The absolute number of F4/80+ and Arginase-1+ cells per 20× field was quantified by ImageJ and analyzed by GraphPad. (C and D) The effects of MNK inhibitors on the number of TAMs (CD11b+F4/80+) and their expression of Arginase-1 (Arg-1hiF4/80+) were analyzed by flow cytometry. (E) TAMs (CD45+CD11b+F4/80+) collected from mice treated with DMSO, CGP57380, or eFT508 were cocultured with CFSE-stained splenic CD8+ T cells for 96 hours. T cell proliferation, as determined by the percentages of dividing T cells and T cell numbers, was analyzed by flow cytometry. Data are shown as the mean ± SEM. Data points in A–D represent individual tumors, and data points in E represent biological replicates. Analysis was done using 1-way ANOVA followed by Dunnett’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.